Clinical features of metastatic bone disease and risk of skeletal morbidity

被引:1712
作者
Coleman, Robert E. [1 ]
机构
[1] Weston Pk Hosp, Acad Unit Med Oncol, Sheffield, S Yorkshire, England
关键词
D O I
10.1158/1078-0432.CCR-06-0931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The skeleton is the most common organ to be affected by metastatic cancer and the site of disease that produces the greatest morbidity. Skeletal morbidity includes pain that requires radiotherapy, hypercalcemia, pathologic fracture, and spinal cord or nerve root compression. From randomized trials in advanced cancer, it can be seen that one of these major skeletal events occurs on average every 3 to 6 months. Additionally, metastatic disease may remain confined to the skeleton with the decline in quality of life and eventual death almost entirely due to skeletal complications and their treatment. The prognosis of metastatic bone disease is dependent on the primary site, with breast and prostate cancers associated with a survival measured in years compared with lung cancer, where the average survival is only a matter of months. Additionally the presence of extraosseous disease and the extent and tempo of the bone disease are powerful predictors of outcome. The latter is best estimated by measurement of bone-specific markers, and recent studies have shown a strong correlation between the rate of bone resorption and clinical outcome, both in terms of skeletal morbidity and progression of the underlying disease or death. Our improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of healthcare resources.
引用
收藏
页码:6243S / 6249S
页数:7
相关论文
共 42 条
  • [1] [Anonymous], 1981, Bone metastases
  • [2] BATAILLE R, 1992, BLOOD, V80, P733
  • [3] The role of the vertebral veins in metastatic processes
    Batson, OV
    [J]. ANNALS OF INTERNAL MEDICINE, 1942, 16 (01) : 38 - 45
  • [4] URINARY PYRIDINIUM CROSS-LINKS AS MARKERS OF BONE-RESORPTION IN TUMOR-ASSOCIATED HYPERCALCEMIA
    BODY, JJ
    DELMAS, PD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) : 471 - 475
  • [5] Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    Brown, JE
    Cook, RJ
    Major, P
    Lipton, A
    Saad, F
    Smith, M
    Lee, KA
    Zheng, M
    Hei, YJ
    Coleman, RE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 59 - 69
  • [6] Bone resorption predicts for skeletal complications in metastatic bone disease
    Brown, JE
    Thomson, CS
    Ellis, SP
    Gutcher, SA
    Purohit, OP
    Coleman, RE
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (11) : 2031 - 2037
  • [7] PARATHYROID-HORMONE RELATED PROTEIN AND SKELETAL MORBIDITY IN BREAST-CANCER
    BUNDRED, NJ
    WALKER, RA
    RATCLIFFE, WA
    WARWICK, J
    MORRISON, JM
    RATCLIFFE, JG
    [J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) : 690 - 692
  • [8] Coleman R, 1987, BRIT J CANCER, V77, P336
  • [9] COLEMAN RE, 1988, EUR J SURG ONCOL, V14, P423
  • [10] Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Coleman, RE
    Major, P
    Lipton, A
    Brown, JE
    Lee, KA
    Smith, M
    Saad, F
    Zheng, M
    Hei, YJ
    Seaman, J
    Cook, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 4925 - 4935